Association of Colchicine Price and Emergency Department Visits for Gout?

MICHAEL E. MULLINS

J Rheumatol 2017;44;397
http://www.jrheum.org/content/44/3/397

1. Sign up for TOCs and other alerts
   http://www.jrheum.org/alerts

2. Information on Subscriptions
   http://jrheum.com/faq

3. Information on permissions/orders of reprints
   http://jrheum.com/reprints_permissions

The Journal of Rheumatology is a monthly international serial edited by Earl D. Silverman featuring research articles on clinical subjects from scientists working in rheumatology and related fields.
Association of Colchicine Price and Emergency Department Visits for Gout?

To the Editor:

In reading the recent article by Jinno, et al,1 I perceive an inflection in the curve for emergency department (ED) visits per 100,000 people in 2009 (Figure 1). This coincides with the US Food and Drug Administration (FDA), Rockville, Maryland, approval of colchicine in July 2009 and the beginning of the manufacturer’s campaign to drive competing “unapproved” colchicine from the market. These events may have influenced any of the trends observed. The FDA approval gave Mutual Pharmaceutical Company (later URL Pharma) 3 years of market exclusivity for gout and 7 years of market exclusivity for familial Mediterranean fever. The result was an immediate 50-fold price increase from about $0.10 per tablet to $5.00 per tablet2,3. I wonder how much the sharp change in cost and availability of colchicine contributed to the increase in ED visits after 2009.

MICHAEL E. MULLINS, MD, FAACT, FACEP, Associate Professor, Emergency Medicine, Washington University School of Medicine, 660 S. Euclid Ave., Campus Box 8072, St. Louis, Missouri 63110-1010, USA. E-mail: mullinsm@wustl.edu

REFERENCES


J Rheumatol 2017;44:3; doi:10.3899/jrheum.160788

Figure 1. Number of visits to the emergency department for gout per 100,000 people in the United States, 2006–2012. Colchicine was approved by US authorities in 2009.